Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Nov 19;8(1):4-7.
doi: 10.1016/j.ekir.2022.11.006. eCollection 2023 Jan.

Every Fifteen Days Forever?

Marina Noris  1 , Giuseppe Remuzzi  1
Affiliations
Editorial

Every Fifteen Days Forever?

Marina Noris et al. Kidney Int Rep. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overview of the outcome of patients with aHUS after eculizumab discontinuation. Published data from patients who were in full remission at the time of discontinuation and who underwent screening for abnormalities in complement genes have been considered., , , ,S2–S4 CFB, complement factor B; CFH, complement factor H; CFI, complement factor I; MCP, membrane cofactor protein; YES, complement gene variants identified; NO, no gene abnormality identified.
See this image and copyright information in PMC

Comment on

  • doi: 10.1016/j.ekir.2022.10.013

References

    1. Noris M., Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:1676–1687. doi: 10.1056/NEJMra0902814. - DOI - PubMed
    1. Mele C., Remuzzi G., Noris M. Hemolytic uremic syndrome. Semin Immunopathol. 2014;36:399–420. doi: 10.1007/s00281-014-0416-x. - DOI - PubMed
    1. Noris M., Caprioli J., Bresin E., et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5:1844–1859. doi: 10.2215/CJN.02210310. - DOI - PMC - PubMed
    1. Legendre C.M., Licht C., Muus P., et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169–2181. doi: 10.1056/NEJMoa1208981. - DOI - PubMed
    1. Fakhouri F., Loirat C. Anticomplement treatment in atypical and typical hemolytic uremic syndrome. Semin Hematol. 2018;55:150–158. doi: 10.1053/j.seminhematol.2018.04.009. - DOI - PubMed

Publication types

LinkOut - more resources